HomeCompareTBET vs PM

TBET vs PM: Dividend Comparison 2026

TBET yields 2000000.00% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBET wins by $6.611489921451573e+26M in total portfolio value
10 years
TBET
TBET
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-41.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.611489921451573e+26M
Annual income
$647,117,451,910,057,200,000,000,000,000,000.00
Full TBET calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — TBET vs PM

📍 TBET pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBETPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBET + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBET pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBET
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$550,049,834,123,548,600,000,000,000,000,000.00/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, TBET beats the other by $550,049,834,123,548,600,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBET + PM for your $10,000?

TBET: 50%PM: 50%
100% PM50/50100% TBET
Portfolio after 10yr
$3.305744960725786e+26M
Annual income
$323,558,725,955,028,600,000,000,000,000,000.00/yr
Blended yield
97.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

TBET
No analyst data
Altman Z
2.8
Piotroski
5/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBET buys
0
PM buys
0
No recent congressional trades found for TBET or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBETPM
Forward yield2000000.00%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-41.7%17.2%
Portfolio after 10y$6.611489921451573e+26M$49.6K
Annual income after 10y$647,117,451,910,057,200,000,000,000,000,000.00$2,492.02
Total dividends collected$6.60220963740724e+26M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TBET vs PM ($10,000, DRIP)

YearTBET PortfolioTBET Income/yrPM PortfolioPM Income/yrGap
1← crossover$116,610,700$116,600,000.00$11,648$408.29+$116.60MTBET
2$740,960,179,286$740,835,405,837.38$13,589$495.90+$740960.17MTBET
3$2,565,648,744,625,911$2,564,855,917,234,074.00$15,877$603.21+$2565648744.61MTBET
4$4,841,683,490,779,422,000$4,838,938,246,622,672,000.00$18,580$734.88+$4841683490779.40MTBET
5$4,980,649,939,169,679,000,000$4,975,469,337,834,545,000,000.00$21,781$896.75+$4980649939169679.00MTBET
6$2,794,072,047,552,133,300,000,000$2,788,742,752,117,221,600,000,000.00$25,578$1,096.12+$2794072047552133120.00MTBET
7$855,392,350,743,088,900,000,000,000$852,402,693,652,208,300,000,000,000.00$30,092$1,342.17+$855392350743088857088.00MTBET
8$143,101,438,587,633,330,000,000,000,000$142,186,168,772,338,260,000,000,000,000.00$35,470$1,646.46+$1.4310143858763332e+23MTBET
9$13,113,589,004,766,448,000,000,000,000,000$12,960,470,465,477,680,000,000,000,000,000.00$41,892$2,023.58+$1.311358900476645e+25MTBET
10$661,148,992,145,157,300,000,000,000,000,000$647,117,451,910,057,200,000,000,000,000,000.00$49,578$2,492.02+$6.611489921451573e+26MTBET

TBET vs PM: Complete Analysis 2026

TBETStock

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women's anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. The company also develops Xuezang Guben pill indicated for the treatment of neurasthenia, insomnia, frequent urination, nocturnal emission, and women's menopausal symptoms; Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B. In addition, it focuses to commercialize Wupeng Pill for treating echimococosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. The company was formerly known as Shangri-La Tibetan Pharmaceuticals, Inc. and changed its name to Tibet Pharmaceuticals Inc. in July 2010. Tibet Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Wanchai, Hong Kong.

Full TBET Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this TBET vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBET vs SCHDTBET vs JEPITBET vs OTBET vs KOTBET vs MAINTBET vs MOTBET vs BTITBET vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.